Cargando…
Duloxetine in the treatment of major depressive disorder: an open-label study
BACKGROUND: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants exhibiting dual reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE) may achieve higher r...
Autores principales: | Hudson, James I, Perahia, David G, Gilaberte, Inmaculada, Wang, Fujun, Watkin, John G, Detke, Michael J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2018694/ https://www.ncbi.nlm.nih.gov/pubmed/17725843 http://dx.doi.org/10.1186/1471-244X-7-43 |
Ejemplares similares
-
Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
por: Wohlreich, Madelaine M, et al.
Publicado: (2004) -
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006) -
Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005) -
Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013) -
Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)